Nidhin Augustine Joseph

human being

[Nidhin Augustine Joseph @NidhinAugustin4]

@Chris369M @Riuan222 Dayavu cheythu malayalikalodulla bahumaanam kalayaruthu.

[Nidhin Augustine Joseph @NidhinAugustin4]

@TheBull_Stocks $AIFF

[Nidhin Augustine Joseph @NidhinAugustin4]

RT @Geiger_Capital: Trump needs to make a call before Belgium…

[Nidhin Augustine Joseph @NidhinAugustin4]

@stockplaymaker1 I scalped it

[Nidhin Augustine Joseph @NidhinAugustin4]

@stockplaymaker1 What about $ANNA

[Nidhin Augustine Joseph @NidhinAugustin4]

@IdenixH I buyed 50k share at 6.9
This company's future revenue after Saudi and Europe approval going to hit massively and it will expand other countries too,strong fundamental.
Ibrx will hit $20 soon .

[Mindy Kitei: journalist @CFSCentral]

Keytruda was approved in a single-arm study 4 papillary non-muscle-invasive bladder cancer (NMIBC). Dr. Soon-Shiong has submitted results w Anktiva to FDA for NMIBC approval.

Keytruda was *not* approved based on a double-blind, randomized trial. In a single-arm study, every participant received Keytruda. There was *no* placebo or comparison group.

Yet, FDA wanted Dr. Soon-Shiong to use a placebo or comparison group for Anktiva. He didn't do this, as he found it to be ethically problematic.

Instead, he supplied data from patients followed after Anktiva + BCG treatment for at least 3 yrs.

There is a double standard at FDA for Keytruda & Anktiva. Anktiva was on the scene long before Keytruda. A comparison of the studies, below, show it's the superior drug.

FDA favored Keytruda, letting a lesser drug skate through, while it makes Anktiva jump through hoops.

That's because ImmunityBio is a small company, while Keytruda is made by Merck. The regulatory inconsistencies are due to the Big Pharma effect.

Anktiva’s outcomes for papillary NMIBC are already stronger than Keytruda’s. Randomizing patients to a weaker treatment like standard chemo or Keytruda when a more effective one exists I believe is ethically wrong.

We need a paradigm shift at FDA. We have decades of data that can be used as comparisons in these drug trials.

Sick participants entering drug trials have enough to worry about w/out getting lesser drugs or placebos, don't they?

Here's the NMIBC disease-free comparison at 2 yrs, courtesy of ChatGPT:

Keytruda: ~42-44% disease-free at 12 months.
Anktiva+BCG: ~58% disease-free at 12 months.

Keytruda: ~30–40% disease-free at 24 months.
Anktiva+BCG ~52% disease-free at 24 months.

And at 3 years:
82% of Anktiva + BCG patients kept their bladders.
73% of Keytruda patients kept their bladders.

Keytruda patients disease free: 35%
Anktiva + BCG disease-free: 38%

Keytruda disease-specific survival not reported; overall survival: ~90%
Anktiva + BCG disease-specific survival: ~96%

@DrPatrick
@ImmunityBio
@DrMakaryFDA
@DrJBhattacharya
@ChrisCuomo
@SecKennedy
@LoriMills4CA42
@tteuscher
@CarnivoreKen

[Nidhin Augustine Joseph @NidhinAugustin4]

https://t.co/qlV1aUzfTL

[Nidhin Augustine Joseph @NidhinAugustin4]

$IBRX
Officially approved in EUROPE 🇪🇺

[Nidhin Augustine Joseph @NidhinAugustin4]

$ibrx
I am holding some share and I like to tell everyone,this post is not for any game plan but the whole world should know that arrival of the drug that cure cancer , congratulations the team #immunitybio and God bless you @DrPatrick . More to come ...
#CANCERCURE .

[Nidhin Augustine Joseph @NidhinAugustin4]

@stockplaymaker1 $12

[Nidhin Augustine Joseph @NidhinAugustin4]

@stockplaymaker1 It's me sadly 😥

[Nidhin Augustine Joseph @NidhinAugustin4]

@jasonlewris Yesterday it was$28.2 M ahead and today $29.3M, calculation mistake?

[Nidhin Augustine Joseph @NidhinAugustin4]

@trentkelp $ 1 TO $10 within a mnth, you have no credibility to talk a shit about this stock further.

[Nidhin Augustine Joseph @NidhinAugustin4]

@nejatian Good luck and rebuild it.

[chun choi @Bchoi_169]

$open

[Grow Fund @growfund_]

$OPEN

[Nidhin Augustine Joseph @NidhinAugustin4]

@ericjackson Thanks, Eric, and open army we achieved it.

[Nidhin Augustine Joseph @NidhinAugustin4]

$OPEN ... Buy more and hold until hits $82.